Amedeo Smart

Free Medical Literature Service


 

Amedeo

Colorectal Neoplasms

  Free Subscription

Articles published in
Clin Cancer Res
    December 2017
  1. LIANG Q, Ma D, Zhu X, Wang Z, et al
    RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer.
    Clin Cancer Res. 2017 Dec 29. pii: 1078-0432.CCR-17-2133.
    >> Share

  2. DIENSTMANN R
    Tumor side as model of integrative molecular classification of colorectal cancer.
    Clin Cancer Res. 2017 Dec 21. pii: 1078-0432.CCR-17-3477.
    >> Share

  3. SVEEN A, Bruun J, Eide PW, Eilertsen IA, et al
    Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies.
    Clin Cancer Res. 2017 Dec 14. pii: 1078-0432.CCR-17-1234.
    >> Share

  4. BERGER MD, Stintzing S, Heinemann V, Cao S, et al
    A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1663.
    >> Share

  5. ULINTZ PJ, Greenson JK, Wu R, Fearon ER, et al
    Lymph Node Metastases in Colon Cancer are Polyclonal.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-1425.
    >> Share

  6. CARNERO A, Lucena-Cacace A, Otero-Albiol D, Jimenez-Garcia MP, et al
    NAMPT is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and resistance to therapy through Sirt1 and PARP.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2575.
    >> Share

    November 2017
  7. LOREE JM, Pereira AA, Lam M, Willauer AN, et al
    Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2484.
    >> Share

    October 2017
  8. GROTHEY A, Strosberg JR, Renfro LA, Hurwitz HI, et al
    A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Ontuxizumab (MORAb-004) in Patients with Chemorefractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.1558.2017.
    >> Share

  9. LAL N, White BS, Goussous G, Pickles OJ, et al
    KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1090.2017.
    >> Share

  10. BOCCACCIO C, Luraghi P, Bigatto V, Cipriano E, et al
    A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.2151.2017.
    >> Share

    September 2017
  11. KANG DW, Lee BH, Suh YA, Choi YS, et al
    Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt/beta-catenin and PI3K/Akt Signaling.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0749.2017.
    >> Share

  12. JOUNG JG, Oh BY, Hong HK, AlKhalidi H, et al
    Tumor heterogeneity predicts metastatic potential in colorectal cancer.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0306.2017.
    >> Share

  13. YIN Y, Yao S, Hu Y, Feng Y, et al
    The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-derived IL-6.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1283.2017.
    >> Share

  14. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    >> Share

  15. JIAO HL, Ye YP, Yang RW, Sun HY, et al
    Down-regulation of SAFB sustains the NF-kappaB pathway by targeting TAK1 during the progression of colorectal cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0747.2017.
    >> Share

    August 2017
  16. SCURR MJ, Pembroke T, Bloom A, Roberts DJ, et al
    Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0895.2017.
    >> Share

    June 2017
  17. YAO YM, Donoho GP, Iversen P, Zhang Y, et al
    Mouse PDX Trial Suggests Synergy of concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS mutations.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3250.2016.
    >> Share

  18. PEKOW J, Meckel K, Dougherty U, Huang Y, et al
    miR-193a-3p is a key tumor suppressor in ulcerative colitis-associated colon cancer and promotes carcinogenesis through up-regulation of IL17RD.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0171.2017.
    >> Share

  19. SCHOLER LV, Reinert T, Orntoft MW, Kassentoft CG, et al
    Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0510.2017.
    >> Share

  20. PRIEUR A, Cappellini M, Habif G, Lefranc MP, et al
    Targeting the Wnt pathway and cancer stem cells with anti-progastrin humanized antibodies: a major breakthrough for K-RAS mutated colorectal cancer treatment.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0533.2017.
    >> Share

  21. GARLAN F, Laurent-Puig P, Sefrioui D, Siauve N, et al
    Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study).
    Clin Cancer Res. 2017 Jun 2. pii: clincanres.3155.2016.
    >> Share

    May 2017
  22. STIEGELBAUER V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, et al
    MicroRNA-196b-5p regulates colorectal cancer cell migration and metastases through interaction of HOXB7 and GALNT5.
    Clin Cancer Res. 2017 May 22. pii: clincanres.0023.2017.
    >> Share

  23. GOLDSTEIN JB, Wu W, Borras E, Masand G, et al
    Can Microsatellite Status of Colorectal Cancer be Reliably Assessed after Neoadjuvant Therapy?
    Clin Cancer Res. 2017 May 18. pii: clincanres.2994.2016.
    >> Share

    April 2017
  24. XU JM, Wang Y, Wang YL, Wang Y, et al
    PIK3CA mutations contribute to acquired cetuximab resistance in metastatic colorectal cancer patients.
    Clin Cancer Res. 2017 Apr 19. pii: clincanres.2738.2016.
    >> Share

  25. THIERRY AR, Pastor B, Jiang ZQ, Katsiampoura A, et al
    Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0232.2017.
    >> Share

    March 2017
  26. CARBONE C, Piro G, Simionato F, Ligorio F, et al
    Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3153.2016.
    >> Share

  27. PARSEGHIAN C, Parikh NU, Wu JY, Jiang ZQ, et al
    Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.3138.2016.
    >> Share

    February 2017
  28. WENG W, Wei Q, Toden S, Yoshida K, et al
    Circular RNA ciRS-7 - A promising prognostic biomarker and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.2541.2016.
    >> Share

    January 2017
  29. GOVERNA V, Trella E, Mele V, Tornillo L, et al
    The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2047.2016.
    >> Share

    November 2016
  30. BLAJ C, Bringmann A, Schmidt EM, Urbischek M, et al
    ADNP is a therapeutically inducible repressor of WNT signaling in colorectal cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1604.2016.
    >> Share

  31. SUMMERS M, Smith CG, Maughan TS, Kaplan R, et al
    BRAF and NRAS locus specific variants have different outcomes on survival to colorectal cancer.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1541.2016.
    >> Share

    October 2016
  32. PIETRANTONIO F, Vernieri C, Siravegna G, Mennitto A, et al
    Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1863.2016.
    >> Share

  33. LIANG JQ, Chiu J, Chen Y, Huang Y, et al
    Fecal Bacteria Act as Novel Biomarkers for Non-Invasive Diagnosis of Colorectal Cancer.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.1599.2016.
    >> Share

  34. NEGRI FV, Boggiani D, Rimanti A, Musolino A, et al
    FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.
    Clin Cancer Res. 2016;22:4958.
    >> Share

    September 2016
  35. MA Y, Wang L, Neitzel LR, Loganathan S, et al
    The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0453.2016.
    >> Share

  36. PARK JH, Van Wyk HC, McMillan DC, Quinn JA, et al
    Signal transduction and activator of transcription-3 (STAT3) in patients with colorectal cancer: associations with the phenotypic features of the tumour and host.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1416.2016.
    >> Share

  37. SALVUCCI M, Wurstle ML, Morgan C, Curry S, et al
    A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1084.2016.
    >> Share

    August 2016
  38. SHIGEYASU K, Okugawa Y, Toden S, Boland CR, et al
    Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1023.2016.
    >> Share

  39. WEI TT, Lin YT, Tseng RY, Shun CT, et al
    Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2016;22:4158-69.
    >> Share

  40. TOFFOLI G, Sharma MR, Marangon E, Posocco B, et al
    Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients.
    Clin Cancer Res. 2016 Aug 9. pii: clincanres.1012.2016.
    >> Share

  41. YAMAMOTO T, Kawada K, Itatani Y, Inamoto S, et al
    Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-associated Neutrophils through CCL15-CCR1 Axis.
    Clin Cancer Res. 2016 Aug 4. pii: clincanres.0520.2016.
    >> Share

  42. MUSTAFI R, Dougherty U, Mustafi D, Ayaloglu-Butun F, et al
    ADAM17 is a tumor promoter and therapeutic target in Western diet-associated colon cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.3140.2016.
    >> Share


  43. Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    Clin Cancer Res. 2016;22:3982.
    >> Share

    July 2016
  44. TRINH A, Trumpi K, de Sousa E Melo F, Wang X, et al
    Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Clin Cancer Res. 2016 Jul 26. pii: clincanres.0680.2016.
    >> Share

  45. QIAN DC, Xiao X, Byun J, Suriawinata AA, et al
    PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0623.2016.
    >> Share

  46. DE ROBERTIS M, Loiacono L, Fusilli C, Poeta LM, et al
    Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.0709.2016.
    >> Share

  47. BENSON AB, Kiss I, Bridgewater J, Eskens FA, et al
    BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.3117.2016.
    >> Share

    June 2016
  48. BARRAS D, Missiaglia E, Wirapati P, Sieber OM, et al
    BRAF V600E mutant colorectal cancer subtypes based on gene expression.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0140.2016.
    >> Share

  49. KUROIWA-TRZMIELINA J, Wang F, Rapkins RW, Ward RL, et al
    SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2765.2015.
    >> Share

    May 2016
  50. LIU G, Tu D, Lewis M, Cheng D, et al
    Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
    Clin Cancer Res. 2016;22:2435-44.
    >> Share

  51. MUNAKATA K, Uemura M, Tanaka S, Kawai K, et al
    Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
    Clin Cancer Res. 2016 May 10. pii: clincanres.1945.2015.
    >> Share

  52. WENG W, Okugawa Y, Toden S, Toiyama Y, et al
    FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor suppressive miR-342 in human colorectal cancer.
    Clin Cancer Res. 2016 May 9. pii: clincanres.0360.2016.
    >> Share

  53. DUNNE PD, McArt DG, Bradley CA, O'Reilly PG, et al
    Challenging the cancer molecular stratification dogma: Intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer.
    Clin Cancer Res. 2016 May 5. pii: clincanres.0032.2016.
    >> Share

    April 2016
  54. MEYN RE, Krishnan S, Skinner HD
    Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.
    Clin Cancer Res. 2016;22:1834-6.
    >> Share

  55. HILL EJ, Roberts C, Franklin JM, Enescu M, et al
    Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.
    Clin Cancer Res. 2016;22:1922-31.
    >> Share

  56. FERREIRO-NEIRA I, Torres NE, Liesenfeld LF, Chan CH, et al
    XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
    Clin Cancer Res. 2016;22:1663-73.
    >> Share

    February 2016
  57. DUDLEY JC, Lin MT, Le DT, Eshleman JR, et al
    Microsatellite Instability as a Biomarker for PD-1 Blockade.
    Clin Cancer Res. 2016;22:813-20.
    >> Share

  58. MEULENDIJKS D, Jacob W, Martinez-Garcia M, Taus A, et al
    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:877-85.
    >> Share

  59. PATNAIK A, Weiss GJ, Leonard JE, Rasco DW, et al
    Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2016;22:827-36.
    >> Share

  60. MEULENDIJKS D, Lassen UN, Siu LL, Huitema AD, et al
    Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:858-67.
    >> Share

  61. SCHELL MJ, Yang M, Missiaglia E, Delorenzi M, et al
    A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Clin Cancer Res. 2016;22:734-45.
    >> Share

  62. XU L, Ziegelbauer J, Wang R, Wu WW, et al
    Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer.
    Clin Cancer Res. 2016;22:773-84.
    >> Share

  63. ARQUES O, Chicote I, Puig I, Tenbaum SP, et al
    Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Clin Cancer Res. 2016;22:644-56.
    >> Share

    January 2016
  64. ZIEMKE EK, Dosch JS, Maust JD, Shettigar A, et al
    Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
    Clin Cancer Res. 2016;22:405-14.
    >> Share

  65. TURKSMA AW, Coupe VM, Shamier MC, Lam KL, et al
    Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.
    Clin Cancer Res. 2016;22:346-56.
    >> Share

  66. INAMOTO S, Itatani Y, Yamamoto T, Minamiguchi S, et al
    Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis.
    Clin Cancer Res. 2016;22:492-501.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016